Enterprise Value to EBITDA Ratio: Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX) plans to monetize the implementation of bifunctional antibodies for the therapy of head and neck cancer. The EV/EBITDA ratio history for the business demonstrates valuation dynamics, where the 0.00 mark indicates the company's valuation level. Cash flows remain volatile due to the stages of clinical trials. The absence of profitable products leaves the issuer's financial condition dependent on venture capital investments.
bicara.com (BCAX) - metric breakdowns and financial figures
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Bicara Therapeutics Inc.|BCAX - Long-Term Debt to Equity|Short-Term Debt to Capital Bicara Therapeutics|BCAX - Company Total Debt Obligations|Debts to Book Capitalization Bicara Corp|BCAX - Company Long-Term Liabilities|Company Short-Term Debts Bicara Therapeutics|Quick Liquidity bicara.com
- business earnings and investment ratios data:
BCAX - Final Profit|Projected Future Earnings Bicara Therapeutics Inc.|BCAX - P/E Multiple|Projected Price to Earnings Bicara Therapeutics Inc.|BCAX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Bicara Corp|BCAX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Bicara Therapeutics|BCAX - Earnings per share for the trailing year|Quarterly EPS earnings growth bicara.com|BCAX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Bicara Therapeutics Inc.
- company sales and revenue statistics:
Comprehensive company analysis:Bicara Bio BCAX
This indicator compares the aggregate value of assets and debt obligations against operating income to determine the real value of the business, excluding tax and credit burdens. An analysis of the Enterprise Value to EBITDA multiple allows for an assessment of the capitalization efficiency of Bicara Therapeutics Inc. (BCAX) amid investments in bifunctional antibodies and the protection of intellectual property.
Competitors of Bicara Therapeutics Inc. (BCAX)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|PSNL (Personalis Corp) - EV/EBITDA Multiple|Company Value to EBITDA Erasca Oncology ERAS|EV/EBITDA Multiple DCTH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization YMAB (ymabs.com)|EV/EBITDA Multiple AURA (Aura Biosciences)|Total Company Value to Operating Income Before Depreciation Ratio Candel Therapeutics Inc. (CADL)|Accuray Inc. - EV/EBITDA Multiple|SELLAS Life Sciences (SLS) - Enterprise Value to EBITDA Ratio|ACTU: EV/EBITDA Multiple|citiusonc.com (CTOR) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TuHURA Biosciences Inc.|TARA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FATE|EV/EBITDA Multiple aadibio.com (WHWK)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CSBR|XBIT: Enterprise Value to EBITDA Ratio|CEL-SCI Corporation - Enterprise Value to Operating Income Before Depreciation Ratio|OSTX: EV/EBITDA Multiple|Radiopharm Theranostics Ltd - Business Value to Operating Income Before Depreciation|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Adlai Nortye Limited ANL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Veru (VERU)|TPST (Tempest Therapeutics Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XLO (Xilio Therapeutics)|EV/EBITDA Multiple Renovaro Biosciences RENB|MURA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KAPA|OKUR: EV/EBITDA Multiple|Company Value to EBITDA CytoMed Therapeutics Limited (GDTC)|Enterprise Value to EBITDA Ratio CRIS|EV/EBITDA Multiple Apollomics Corp|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ADVB|EV/EBITDA Multiple GNPX (Genprex)|Total Company Value to Operating Income Before Depreciation Ratio Calidi Biotherapeutics Inc. (CLDI)|Sunshine Biopharma - EV/EBITDA Multiple|Xenetic Biosciences (XBIO) - Enterprise Value to EBITDA Ratio|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PPBT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio AONC|BGNE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CKPT|Total Company Value to Operating Income Before Depreciation Ratio Elevation Oncology Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs - EV/EBITDA Multiple|Viracta Therapeutics (VIRX) - Enterprise Value to EBITDA Ratio|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|NAYA - Total Company Value to Operating Income Before Depreciation Ratio|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
